This 1955 CIA document reviews the Agency's research and development of a shocking list of mind-altering substances and methods, including "materials which will render the indication of hypnosis easier or otherwise enhance its usefulness," and "physical methods of producing shock and confusion over extended periods of time and capable of surreptitious use."
5 May 1955
A portion of the Research and Development Program of TSS/Chemical Division is devoted to the discovery of the following materials and methods:
1. Substances which will promote illogical thinking and impulsiveness to the point where the recipient would be discredited in public.
2. Substances which increase the efficiency of mentation and perception.
3. Materials which will prevent or counteract the intoxicating effect of alcohol.
4. Materials which will promote the intoxicating effect of alcohol.
5. Materials which will produce the signs and symptoms of recognized diseases in a reversible way so that they may be used for malingering, etc.
6. Materials which will render the indication of hypnosis easier or otherwise enhance its usefulness.
7. Substances which will enhance the ability of individuals to withstand privation, torture and coercion during interrogation and so-called "brainwashing".
8. Materials and physical methods which will produce amnesia for events preceding and during their use.
9. Physical methods of producing shock and confusion over extended periods of time and capable of surreptitious use.
10. Substances which produce physical disablement such as paralysis of the legs, acute anemia, etc.
11. Substances which will produce "pure" euphoria with no subsequent let-down.
12. Substances which alter personality structure in such a way that the tendency of the recipient to become dependent upon another person is enhanced.
13. A material which will cause mental confusion of such a type that the individual under its influence will find it difficult to maintain a fabrication under questioning.
14. Substances which will lower the ambition and general working efficiency of men when administered in undetectable amounts.
15. Substances which will promote weakness or distortion of the eyesight or hearing faculties, preferably without permanent effects.
16. A knockout pill which can surreptitiously be administered in drinks, food, cigarettes, as an aerosol, etc., which will be safe to use, provide a maximum of amnesia, and be suitable for use by agent types on an ad hoc basis.
17. A material which can be surreptitiously administered by the above routes and which in very small amounts will make it impossible for a man to perform any physical activity whatever.
The development of materials of this type follows the standard practice of such ethical drug houses as [deleted]. It is a relatively routine procedure to develop a drug to the point of human testing. Ordinarily, the drug houses depend upon the services of private physicians for the final clinical testing. The physicians are willing to assume the responsibility of such tests in order to advance the science of medicine. It is difficult and sometimes impossible for TSS/CD to offer such an inducement with respect to its products. In practice, it has been possible to use the outside cleared contractors for the preliminary phases of this work. However, that part which involves human testing at effective dose levels presents security problems which cannot be handled by the ordinary contractor.
The proposed facility [deleted] offers a unique opportunity for the secure handling of such clinical testing in addition to the many advantages outline in the project proposal. The security problems mentioned above are eliminated by the fact that the responsibility for the testing will rest completely with the physician and the hospital. [deleted] will allow TSS/CD personnel to supervise the work very closely to make sure that all tests are conducted according to the recognized practices and embody adequate safeguards.
|All times are GMT -6. The time now is 06:29 PM.|
Powered by vBulletin® Version 3.6.12
Copyright ©2000 - 2017, Jelsoft Enterprises Ltd.